PPGN PolyPeptide Group AG

49.48USD41.70 CHF · SWX+1.58%Mkt Cap: 1.63B USDP/E: 101.71

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceut…

Institutional holders10 on file

Key Statistics

Company
Market Cap1.63B USD
Enterprise Value1.74B USD
Revenue (TTM)503.28M USD
Gross Profit72.98M USD
Net Income (TTM)-23.22M USD
Revenue/Share15.43 USD
Last Price49.48 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.5K
CountryCH
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINCH1110760852
Valuation
P/E (Trailing)101.71
P/E (Forward)29.78
PEG—
EV/EBITDA19.44
EV/Revenue3.46
P/S3.00
P/B4.23
EPS (TTM)0.45 USD
EPS (Forward)1.54 USD
52W Range
25.8770% of range59.45
52W High59.45 USD
52W Low25.87 USD
Profitability
Gross Margin16.98%
Oper. Margin9.63%
EBITDA Margin16.44%
Profit Margin-5.40%
ROE-6.22%
ROA-2.56%
ROIC2.19%
ROCE1.36%
Growth
Revenue Growth41.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF85.01M USD
CapEx (TTM)119.45M USD
FCF Margin-20.18%
FCF Yield-6.22%
Net Debt98.91M USD
Net Debt/EBITDA1.20
Net Debt/FCF—
Balance Sheet
Debt/Equity0.38
Current Ratio1.64
Quick Ratio0.76
Book Value/Sh10.80 USD
Cash/Share1.96 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateApr 28, 2022
Pay DateMay 2, 2022
Analyst Consensus
Rating—
Target (Mean)50.89 USD
Upside (mean)+2.8%
Target Range46.07 USD – 52.68 USD
46.07+2.8% to mean52.68
# Analysts5
Ownership
Shares Out.33.02M
Float14.07M
Insiders1.10%
Institutions9.11%
Technical
SMA 5051.16 (-3.3%)
SMA 20045.52 (+8.7%)
Beta1.04
S&P 52W Chg12.00%
Avg Vol (30d)35.28K
Avg Vol (10d)9.56K
Technical Indicators
RSI (14)48.5
MACD-0.7529
MACD Signal-0.8389
MACD Hist.+0.0860
BB Upper52.75 USD
BB Middle49.35 USD
BB Lower45.95 USD
BB Width13.78%
ATR (14)0.8497 USD
Vol Ratio (20d)0.61x

About PolyPeptide Group (SWX: PPGN)

›

PolyPeptide Group (SWX: PPGN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 1,460 employees.

The shares were at 41.70 CHF on 19 November 2026, up 73.4% over 52 weeks. Its 52-week range is 21.80 CHF to 50.10 CHF: the price is 16.8% below the high and 91.3% above the low.

At a market capitalisation of 1.38B CHF, it trades at 101.7 times trailing earnings and 29.8 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a premium of 312% for PPGN.

PolyPeptide Group reports return on equity of -6.2%, an operating margin of 9.6% and revenue up 41.6% year over year.

Its debt exceeds its cash by 90.18M EUR, a debt-to-equity ratio of 0.38. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 5 analysts cover the stock; their mean price target of 42.89 CHF is 2.8% above the current price. The next earnings report is expected on 9 March 2027.